No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Climb Bio, Inc. (CLYM) stock was $11.05 as of Oct 5, 2026, 4:00 PM EDT, up 1.01% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +453.5%
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses.
Biotechnology · Wellesley Hills, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.19
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.18
vs Estimate
$-0.21
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CLYM | $632.76M | $11.05 | +1.01% | +453.52% | N/A | N/A | N/A |
| 2FLGT | $637.59M | $22.45 | +4.52% | -1.44% | -22.38% | +8.90% | vs CLYM |
| 3ANGO | $642.31M | $15.54 | +2.85% | +33.32% | -10.80% | -0.58% | vs CLYM |
| 4AURA | $643.37M | $6.22 | +2.13% | +2.80% | N/A | N/A | vs CLYM |
| 5ACRS | $596.36M | $4.27 | -2.73% | +128.66% | -24.23% | -16.23% | vs CLYM |
| 6FDMT | $675.41M | $12.92 | -5.49% | +50.81% | -13.08% | N/A | vs CLYM |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 14 analysts
Average Price Target
$27.57
+149.5% upside
Low
$18.00
Current
$11.05
High
$40.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.23 | $-0.20 | $-0.17 | 8 |
| Quarter ending Dec 2026 | $-0.26 | $-0.21 | $-0.17 | 8 |
| Quarter ending Mar 2027 | $-0.23 | $-0.23 | $-0.23 | 3 |
| Quarter ending Jun 2027 | $-0.24 | $-0.24 | $-0.24 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.86 | $-0.79 | $-0.71 | 11 |
| FY 2027 | $-1.10 | $-0.98 | $-0.89 | 11 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $750000.00 | $750000.00 | $750000.00 | 15 |
